Klippel-Trénaunay syndrome (KTS) is a rare congenital vascular disorder defined by a classic triad: a port-wine stain (capillary malformation), abnormal veins or varicose veins, and overgrowth of bone and soft tissue, usually affecting one limb. The condition is present from birth, though it can take years for the full picture to emerge, and the severity varies enormously from person to person. There is no cure, but a growing understanding of the genetic roots of KTS and an expanding toolkit of treatments mean that most people can manage symptoms effectively with the right team of specialists.
The Classic Triad and How It Shows Up
The hallmark description of KTS, used since it was first recognized in the early 1900s, centers on three features appearing together: capillary malformations on the skin (port-wine stains), unusual varicose veins or deeper venous malformations, and hypertrophy, meaning one limb grows longer or larger than normal. A large series of 252 patients at the Mayo Clinic confirmed this combination as the defining pattern, with most cases involving a single extremity.1Mayo Clinic Proceedings. Klippel-Trénaunay Syndrome: Spectrum and Management
Not everyone with KTS has all three features in equal measure. The port-wine stain is often the first thing noticed at birth, typically a flat, reddish-purple patch on the skin of the affected leg. It can range from a small blotch to a large area covering much of the limb. The venous abnormalities might be obvious varicose veins visible just under the skin, or deeper malformations that only show up on imaging. The overgrowth can affect bone length, the circumference of soft tissue, or both. Some people have a leg that is noticeably longer or thicker than the other; others have differences so subtle they go undetected for years.
Why KTS Happens
For decades, the genetic cause of KTS was unknown. That changed with the discovery that the condition is driven by mutations in a gene called PIK3CA, which plays a role in cell growth and division during embryonic development. These mutations are somatic and mosaic, meaning they arise spontaneously in a single cell early in fetal development and then spread only to the cells descended from that original cell.2PubMed Central. Genetics Corner: Klippel-Trenaunay Syndrome in an Infant with a Mosaic PIK3CA Variant, a Target for the Medical Treatment of Asymmetric Overgrowth The mutation is not present in every cell of the body, which is why the overgrowth and vascular malformations tend to be localized to one region rather than affecting the whole body.
Because the mutation happens after conception, KTS is not inherited from parents in the way conditions like cystic fibrosis or sickle cell disease are. A person with KTS did not receive a faulty gene from either parent, and the chance of passing it to their own children is extremely low. This somatic origin also places KTS within a broader family of conditions called the PIK3CA-related overgrowth spectrum, or PROS, which includes several other syndromes that share overlapping features of tissue overgrowth and vascular anomalies.3PubMed. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS) The recognition that KTS belongs to PROS rather than being a completely standalone diagnosis has reshaped how researchers think about treatment, because therapies targeting the PIK3CA pathway could work across multiple conditions in the spectrum.4PubMed Central. The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes
Beyond the Triad: The Full Range of Symptoms
While the classic three features get the most attention, KTS affects more body systems than many people realize.
Lymphatic Problems
Lymphatic malformations are extremely common in KTS, though they are often underappreciated. A study that carefully imaged 32 patients found lymphatic vessel or lymph node abnormalities in nearly all of them, and every patient in the study had lymphedema of the affected limb.5PubMed. Lymphatic malformation is a common component of Klippel-Trenaunay syndrome Lymphedema causes chronic swelling, heaviness, and a feeling of tightness. It can make the limb more vulnerable to skin infections called cellulitis, which in turn can worsen the lymphatic damage over time.
Musculoskeletal Issues
Limb-length discrepancy is the most common orthopedic problem, documented in roughly 84% of patients in one large review. But the skeleton can be affected in other ways too, including angular deformities of the bones, scoliosis, reduced bone density, and joint contractures.6PubMed Central. Orthopaedic diagnoses in patients with Klippel-Trenaunay syndrome For children, a difference in leg length even of a couple of centimeters can alter gait, stress the hip and spine, and lead to chronic pain if left unaddressed.
Blood Clotting Risks
The abnormal veins in KTS are not just a cosmetic concern. Blood can pool and stagnate in malformed venous channels, raising the risk of deep vein thrombosis and even pulmonary embolism. Some patients develop a chronic low-grade clotting disturbance, sometimes called localized intravascular coagulopathy, in which the abnormal vessels continuously consume clotting factors.7PubMed. Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome This can paradoxically lead to both clotting and bleeding problems at the same time.
Gastrointestinal Involvement
Vascular malformations can extend to internal organs, and the gastrointestinal tract is one of the more serious sites. GI involvement is uncommon, but when it occurs, it can cause life-threatening bleeding.8PubMed Central. Klippel-Trenaunay Syndrome Causing Life-Threatening GI Bleeding: A Case Report and Review of the Literature One case report described a patient with intermittent blood in the stool for years before eventually being hospitalized with massive GI hemorrhage, along with vascular malformations found in the spleen.9PubMed Central. Klippel-Trenaunay syndrome with gastrointestinal bleeding, splenic hemangiomas and left inferior vena cava Any unexplained rectal bleeding or iron deficiency anemia in someone with KTS should prompt investigation of the GI tract.
KTS Versus Parkes Weber Syndrome
One of the more persistent areas of confusion is the relationship between Klippel-Trénaunay syndrome and Parkes Weber syndrome. The two have historically been lumped together under the label “Klippel-Trénaunay-Weber syndrome,” and you will still see that combined name in older textbooks and some clinic descriptions. However, they are now understood as distinct conditions with different underlying vascular problems.
The key difference is the type of blood flow involved. KTS is a purely low-flow vascular condition, meaning the malformations involve veins, capillaries, and lymphatics but not arteries. Parkes Weber syndrome, by contrast, involves significant arteriovenous fistulas, which are abnormal direct connections between arteries and veins that create high-flow, high-pressure shunting of blood.10PubMed. Parkes Weber or Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography This distinction matters because Parkes Weber syndrome can put a greater strain on the heart and often requires different management strategies. Modern imaging, particularly MRI-based vascular studies, can reliably tell the two apart without invasive procedures.
How KTS Is Diagnosed
Diagnosis is primarily clinical, based on the visible and physical features of the condition. Most children with KTS are identified in infancy or early childhood when the port-wine stain and limb asymmetry become apparent. Imaging plays a supporting role in mapping the extent of the malformations and guiding treatment planning.
Doppler ultrasound is typically the first imaging study, useful for characterizing varicose veins, detecting blood clots, and identifying blood flowing backward through incompetent valves. Plain X-rays can document limb-length differences and bone changes. For a more complete picture, MRI and CT angiography help evaluate the deeper vascular anatomy and accompanying soft tissue changes.11PubMed Central. Multimodality imaging approach in a patient with Klippel-Trenaunay syndrome Genetic testing for PIK3CA mutations can confirm the diagnosis when there is uncertainty, though it sometimes requires testing tissue from the affected area rather than a standard blood sample, because the mutation may not be present in blood cells.
Prenatal detection is also possible in some cases. Detailed fetal ultrasound can pick up characteristic features such as limb asymmetry and soft tissue masses, providing an opportunity for early counseling and birth planning.12PubMed Central. Prenatal ultrasonographic findings in Klippel-Trenaunay syndrome: A case report
Treatment Strategies
Because KTS is caused by a somatic mutation that has already shaped the body’s development, treatment focuses on managing symptoms and preventing complications rather than eliminating the underlying condition. Most patients benefit from a combination of approaches, and care usually involves multiple specialties working together.
Compression Therapy
Custom-fitted compression garments are a first-line treatment for managing swelling, pain, and the risk of blood clots in the affected limb. A multi-institutional study found that wearing custom-made compression garments for six months led to a trend toward improvement in both pain scores and functional ability. Participants reported no significant restrictions in daily activities, and while some experienced minor issues like heat or itchiness, the garments were well-tolerated overall.13PubMed Central. A Multi-Institutional Study on the Efficacy and Safety of Wearing a Custom-Made Compression Elastic Garment for 6 Months for Klippel–Trenaunay Syndrome with Venous Malformation The improvements were modest, and compression does not fix the underlying vascular problem, but it remains the backbone of daily management for most patients.
Medications
For clotting risks, anticoagulant therapy (blood thinners) is often necessary, particularly around surgeries or during periods of immobility. The choice of agent varies, but direct oral anticoagulants have been used successfully in some patients with KTS-related coagulopathy.7PubMed. Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome
On the more targeted side, the drug sirolimus has emerged as an effective medical treatment for controlling recurrent bleeding from diffuse skin and mucosal vascular lesions in KTS. Sirolimus works by inhibiting a pathway downstream of PIK3CA, essentially putting the brakes on the overgrowth signals. An even more specific drug, alpelisib, directly inhibits the PI3K enzyme encoded by PIK3CA and is considered a promising future therapy, though clinical experience in KTS specifically remains limited.14Egyptian Pediatric Association Gazette. Klippel-Trenaunay syndrome: a single-center experience with combined slow-flow vascular malformations Alpelisib was originally developed for cancer treatment, and its repurposing for overgrowth syndromes represents one of the more exciting developments in this space.
Laser Treatment for Port-Wine Stains
The port-wine stain birthmarks in KTS can be treated with pulsed-dye laser therapy. One case report documented a two-week-old infant whose port-wine stain disappeared completely after three laser sessions, with no recurrence over seven years of follow-up. The laser also appeared to halt the soft tissue overgrowth in that patient.15PubMed Central. Successful Treatment of Unilateral Klippel-Trenaunay Syndrome With Pulsed-Dye Laser in a 2-Week Old Infant Results vary depending on the size, depth, and location of the birthmark, and multiple sessions are usually needed. Early treatment, particularly in infancy, tends to produce better cosmetic outcomes than waiting.
Surgical Options
Surgery in KTS is reserved for specific situations rather than used as a blanket approach. One important indication involves the lateral marginal vein of Servelle, an embryonic vein that normally disappears during fetal development but persists in some people with KTS. Because this vein lacks proper valves, blood pools and stagnates within it, raising the risk of clotting and recurrent thromboembolism. Surgical removal of this vein, especially at a younger age, can reduce future clotting events.16PubMed Central. A rare case of persistent lateral marginal vein of Servelle in Klippel Trenaunay Syndrome: A successful surgical management
For limb-length discrepancy, orthopedic procedures during childhood can help equalize leg length before the skeleton finishes growing. Epiphyseal stapling, which temporarily slows growth on the longer side, or permanent growth plate surgery (epiphysiodesis) in older children, can achieve adequate correction in most cases.17PubMed. Correction of leg inequality in the Klippel-Trenaunay-Weber syndrome Timing matters: these procedures depend on how much growth the child has left, so regular monitoring of leg length throughout childhood is standard practice.
Sclerotherapy, in which a chemical agent is injected directly into a venous malformation to shrink it, and endovascular procedures to close off abnormal blood vessels are also part of the toolkit. These interventional approaches are typically guided by imaging and performed by vascular or interventional radiologists.
Living with KTS and Its Psychological Toll
The visible nature of KTS, combined with chronic pain and functional limitations, takes a real psychological toll. Research has found that patients with KTS score lower than the general population on measures of mental health, physical function, and overall quality of life.18PubMed. Pain, psychiatric comorbidities, and psychosocial stressors associated with Klippel-Trenaunay syndrome Chronic pain is common and can be difficult to manage. The cosmetic aspects of the condition, particularly visible birthmarks and limb asymmetry, contribute to body image concerns and social anxiety, particularly during adolescence.
Access to psychological support, peer communities, and proactive pain management should be part of the care plan. Because KTS is rare, many patients and families feel isolated and struggle to find providers who understand the condition. Organizations focused on vascular malformations can connect families with specialized centers and support networks. The shift toward multidisciplinary vascular anomaly clinics, where dermatologists, vascular surgeons, orthopedists, hematologists, and mental health professionals collaborate under one roof, has improved the experience for many families navigating this diagnosis.
Pregnancy and KTS
Pregnancy in someone with KTS is manageable but carries elevated risks that require careful planning. The vascular abnormalities already predispose to clotting, and the normal physiological changes of pregnancy, including increased blood volume, hormonal effects on blood vessels, and reduced venous return from the legs, amplify those risks further.19PubMed Central. Pregnancy in women with Klippel-Trenaunay syndrome: Report of three pregnancies in a single patient and review of literature
There are no formal evidence-based guidelines specifically for managing pregnancy in KTS, so care is individualized. In practice, a multidisciplinary team typically devises a high-risk thrombosis management plan that includes compression stockings and preventive anticoagulation with low-molecular-weight heparin throughout pregnancy. Cesarean delivery is frequently chosen based on obstetric considerations and the presence of pelvic or genital vascular malformations that could bleed during vaginal delivery.20PubMed Central. Obstetric management for pregnant women with Klippel-Trenaunay syndrome: A UK case report and review of the literature The key message is that pregnancy is not off the table for people with KTS, but it should be treated as high-risk from the start, ideally with preconception counseling to plan ahead.
What the Genetic Link to PROS Means for Future Treatment
The reclassification of KTS as part of the PIK3CA-related overgrowth spectrum has opened therapeutic doors that did not exist a decade ago. The PIK3CA pathway is one of the most well-studied signaling pathways in cancer biology, which means there is already a pipeline of drugs designed to inhibit it. Sirolimus, already in clinical use for KTS, works on a related part of this pathway. Alpelisib targets the PIK3CA enzyme directly, and early reports in other PROS conditions have been encouraging enough that clinical trials are expanding.4PubMed Central. The Klippel-Trénaunay Syndrome in 2022: Unravelling Its Genetic and Molecular Profile and Its Link to the Limb Overgrowth Syndromes
This represents a genuine shift in the treatment philosophy. For most of its history, KTS management was purely reactive: treat the swelling, correct the leg length, manage the clotting. Now, there is at least the possibility of treating the molecular driver itself, slowing or halting the overgrowth process rather than just dealing with its consequences. Whether these targeted therapies can be started early enough in life to prevent the most significant complications is an active area of research. For families receiving a new KTS diagnosis today, the landscape looks meaningfully different than it did even ten years ago.